Levee Medical, a Durham, NC-based medical device company designing solutions to improve surgical outcomes following prostate cancer, raised USD6.6M in Series A funding.
The backers were not disclosed.
The company intends to use the funds to advance product development, scale infrastructure, and expand the team to support the development of its Voro™ Urologic Scaffold, a bioresorbable post-prostatectomy implant.
Led by Adam Irving, CEO, and Bruce Choi, Founder, and CTO, Levee Medical is committed to designing solutions that aim to reduce complications associated with surgical treatment for prostate cancer. The Voro Urologic Scaffold is the first product Levee plans to bring to market. It is a bioresorbable device designed to be placed during the prostatectomy procedure for the treatment of urinary incontinence. The device is designed to reduce the stress on the urinary sphincter by managing the geometry of the bladder neck and maintaining urethral length, which is the best predictor of post-op incontinence. It is not currently available for sale.
FinSMEs
24/08/2022